{
    "nctId": "NCT03981705",
    "briefTitle": "Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer",
    "officialTitle": "Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "TN ER-/PR-/HER2- Breast Cancer, Triple Negative Breast Cancer, HER2-positive Breast Cancer, ERany/PRany/HER2+ Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 8,
    "primaryOutcomeMeasure": "Complete Pathologic Response (pCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Biopsy proven triple negative (TN) (ER-/PR-/HER2-) or HER2 positive (ERany/PRany/HER2+) breast cancer for which neoadjuvant chemotherapy is planned\n* A biopsy clip placed at the time of diagnostic biopsy\n* 18 years of age or older\n* Must be able to read and write in English due to the importance of survey (questionnaire) completion to meet the study's endpoint - this is justified as there is no individual benefit to study participation\n* Able to provide written consent prior to any research related activities\n\nExclusion Criteria:\n\n* Stage IV breast cancer\n* T4 breast cancer\n* Previous ipsilateral breast cancer\n* Any contraindication for undergoing a contrast-enhanced breast MRI and/or the breast biopsy between chemotherapy and surgery",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}